Company: Valo Therapeutics Ltd.
Job title: Chief Scientific Officer
PeptiCRAd – A Novel Cancer Immunotherapy Approach Targeting Multiple Tumour Antigens 5:15 pm
PeptiCRAd is a cutting-edge cancer immunotherapy approach that targets multiple tumor antigens simultaneously By targeting multiple tumor antigens, PeptiCRAd increases the likelihood of immune recognition and response against a wide range of cancer types PeptiCRAd has the potential to be a highly effective and versatile cancer immunotherapy, with applications in various cancer typesRead more
day: Day Two